A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy

Trial Profile

A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs RG 7916 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Firefish
  • Sponsors Roche
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 1 Jul 2020 to 7 Jul 2020.
    • 05 Sep 2017 Planned End Date changed from 30 May 2020 to 1 Jul 2020.
    • 08 May 2017 According to a PTC Therapeutics media release, data from the first part of this study are expected to be presented at scientific meetings later this year (2017) and early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top